Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders

/PRNewswire/ -- Hemab Therapeutics, a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and...

Related Keywords

Boston ,Massachusetts ,United States ,Denmark ,Copenhagen ,Køavn ,Glanzmann Thrombasthenia ,Christine Borowski ,Uya Chuluunbaatar ,John Maraganore ,Dan Becker ,Benny Sorensen ,Partner At Novo Holdings ,Novo Holdings ,Willebrand Disease ,Deep Track Capital ,Avoro Ventures ,Rock Springs Capital ,Maj Invest Equity ,Managing Director ,Vice President ,Bernard Soulier Syndrome ,Von Willebrand Disease ,Hereditary Hemorrhagic Telangiectasia ,Congenital Antithrombin ,Hemab Therapeutics ,